Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00510588

Acronym

KFO

Enrollment

120

Registered

2007-08-02

Start date

2007-07-31

Completion date

2013-10-31

Last updated

2014-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose Tolerance, Obesity, Stable Coronary Artery Disease

Keywords

adiposity

Brief summary

Chronic inflammatory activation in fat tissue can be the link between adiposity and an increased risk for atherosclerosis. Aim of the study is to investigate how molecular alterations in fat tissue can be influenced by regular physical exercise training alone or in combination with a medical therapy (Glitazon or Metformin) in obese patients with stable CAD and impaired glucose tolerance.

Interventions

OTHERtraining + metformin

regular physical exercise training in combination with metformin for 6 months

OTHERtraining

regular physical exercise training for 6 months

OTHERtraining + glitazon

regular physical exercise training in combination with a glitazon for 6 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

35 Years to 75 Years

Healthy volunteers

Inclusion criteria

* either impaired glucose tolerance (2-h plasma glucose concentration \>7.8 and \<11.1 mmol/L during an oral glucose tolerance test) or impaired fasting glucose (fasting glucose concentration \>6.0 and \<7.0 mmol/L) * coronary artery disease determined by coronary angiography * BMI \> 25 * male patients aged 35-75 years

Exclusion criteria

* diabetes mellitus type 1 * diabetes mellitus type 2 in combination with glycosylates hemoglobin \>6.0%, previous medication with oral antidiabetic agents or insulin, fasting plasma glucose concentration \> 11.0 mmol/L * unstable angina pectoris * indication for coronary artery bypass graft operation * myocardial infarction within the last 3 months * reduced left-ventricular systolic function \< 40 %

Design outcomes

Primary

Measure	Time frame
change in endothelial function in patients with stable coronary artery disease	6 months

Secondary

Measure	Time frame
change in metabolic parameters	6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026